You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDalteparin
Accession NumberDB06779
TypeSmall Molecule
GroupsApproved
DescriptionDalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. LMWHs have a more predictable response, a greater bioavailability, and a longer anti-Xa half life than unfractionated heparin. Dalteparin can also be safely used in most pregnant women. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
Structure
Thumb
Synonyms
Daltepariininatrium
Dalteparin sodium
Dalteparin sodná sůl
Dalteparin Sodyum
Dalteparin-nátrium
Dalteparina sódica
Daltéparine sodique
Dalteparinnatrium
Dalteparino natrio druska
Dalteparinum Natricum
Dalteparyna sodowa
Heparin Fragment KABI 2165
Tedelparin
External Identifiers
  • Kabi-2165
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FragminInjection2500 [iU]/.2mLSubcutaneousPfizer Laboratories Div Pfizer Inc2015-04-01Not applicableUs
FragminInjection25000 [iU]/mLSubcutaneousEisai Inc.1994-12-22Not applicableUs
FragminInjection10000 [iU]/.4mLSubcutaneousEisai Inc.1994-12-22Not applicableUs
FragminInjection12500 [iU]/.5mLSubcutaneousPfizer Laboratories Div Pfizer Inc2015-04-01Not applicableUs
FragminInjection15000 [iU]/.6mLSubcutaneousEisai Inc.1994-12-22Not applicableUs
FragminInjection5000 [iU]/.2mLSubcutaneousPfizer Laboratories Div Pfizer Inc2015-04-01Not applicableUs
FragminInjection5000 [iU]/.2mLSubcutaneousEisai Inc.1994-12-22Not applicableUs
FragminInjection10000 [iU]/mLSubcutaneousEisai Inc.1994-12-22Not applicableUs
FragminInjection15000 [iU]/.6mLSubcutaneousPfizer Laboratories Div Pfizer Inc2015-04-01Not applicableUs
FragminInjection18000 [iU]/.72mLSubcutaneousEisai Inc.1994-12-22Not applicableUs
FragminInjection7500 [iU]/.3mLSubcutaneousPfizer Laboratories Div Pfizer Inc2015-04-01Not applicableUs
FragminInjection7500 [iU]/.3mLSubcutaneousEisai Inc.1994-12-22Not applicableUs
FragminInjection10000 [iU]/mLSubcutaneousEisai Inc.1994-12-22Not applicableUs
FragminInjection18000 [iU]/.72mLSubcutaneousPfizer Laboratories Div Pfizer Inc2015-04-01Not applicableUs
FragminInjection2500 [iU]/.2mLSubcutaneousEisai Inc.1994-12-22Not applicableUs
FragminInjection10000 [iU]/mLSubcutaneousPfizer Laboratories Div Pfizer Inc2015-04-01Not applicableUs
FragminInjection12500 [iU]/.5mLSubcutaneousEisai Inc.1994-12-22Not applicableUs
FragminInjection25000 [iU]/mLSubcutaneousPfizer Laboratories Div Pfizer Inc2015-04-01Not applicableUs
Fragmin 10000 Iu(anti-XA)/0.4mlSolution10000 unitIntravenous; SubcutaneousPfizer Canada Inc2011-02-01Not applicableCanada
Fragmin 10000 Iu(anti-XA)/mlSolution10000 unitIntravenous; SubcutaneousPfizer Canada Inc1995-12-31Not applicableCanada
Fragmin 12500 Iu(anti-XA)/0.5mlSolution12500 unitIntravenous; SubcutaneousPfizer Canada Inc2011-02-01Not applicableCanada
Fragmin 15000 Iu(anti-XA)/0.6mlSolution15000 unitIntravenous; SubcutaneousPfizer Canada Inc2011-02-01Not applicableCanada
Fragmin 18000 Iu(anti-XA)/0.72mlSolution18000 unitIntravenous; SubcutaneousPfizer Canada Inc2011-02-01Not applicableCanada
Fragmin 2500 Iu(anti-factor Xa)/mlSolution2500 unitIntravenous; SubcutaneousPfizer Canada Inc2012-07-25Not applicableCanada
Fragmin 2500 Iu(anti-XA)/0.2mlSolution2500 unitIntravenous; SubcutaneousPfizer Canada Inc1995-12-31Not applicableCanada
Fragmin 25000 Iu(anti-XA)/mlSolution25000 unitIntravenous; SubcutaneousPfizer Canada Inc1997-11-27Not applicableCanada
Fragmin 3500 Iu(anti-factor Xa)/0.28mlSolution3500 unitIntravenous; SubcutaneousPfizer Canada Inc2015-03-25Not applicableCanada
Fragmin 5000 Iu(anti-XA)/0.2mlSolution5000 unitIntravenous; SubcutaneousPfizer Canada Inc1995-12-31Not applicableCanada
Fragmin 7500 Iu(anti-XA)/0.3mlSolution7500 unitIntravenous; SubcutaneousPfizer Canada Inc2011-02-01Not applicableCanada
Fragmin Inj.-liq 2500 Iu(anti-XA)/mlLiquid2500 unitIntravenous; SubcutaneousPharmacia & Upjohn Inc1995-12-312002-07-30Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BoxolPharmacia
EurodalGland
LigoframinPfizer
Low LiquemineRoche
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIS79O08V79F
CAS number9041-08-1
WeightNot Available
Chemical FormulaNot Available
InChI KeyNot Available
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Pharmacology
IndicationDalteparin is used as a prophylaxis for deep-vein thrombosis and pulmonary embolisms in patients undergoing general surgery (e.g., abdominal, gynecologic, urologic), and in patients with acute medical conditions (e.g. cancer, bed rest, heart failure, severe lung disease). It is also used in patients who have severely restricted mobility, which poses a risk for thromboembolic complications. Dalteparin is also used concomitantly with aspirin and/or other therapy (e.g., nitrates, β-adrenergic blockers, clopidogrel, platelet glycoprotein [GP] IIb/IIIa-receptor inhibitors) to reduce the risk of acute cardiac ischemic events. The patients who undergo this treatment combination have unstable angina or non-ST-segment elevation/non-Q-wave myocardial infarction (i.e., non-ST-segment elevation acute coronary syndromes). It is also used in the prevention of clotting during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency.
Structured Indications
PharmacodynamicsDalteparin has an antithrombin binding site that is essential for high affinity binding to the plasma protein antithrombin (ATIII). Anti-Xa activity of plasma is used as both as an estimate of clotting activity, and as a basis to determine dosage. Its use should be avoided in patients with a creatinine clearance less than 20mL/min. In these patients, unfractionated heparin should only be used. As for monitoring, active partial thromboplastin time (aPTT) will only increase at high doses of low molecular weight heparins (LMWH). Therefore, monitoring aPTT is not recommended. However, anti-Xa activity can be measured to monitor the efficacy of the LMWH.
Mechanism of actionDalteparin potentiates the activity of ATIII, inhibiting the formation of both factor Xa and thrombin. The main difference between dalteparin and unfractionated heparin (UH) is that dalteparin preferentially inactivates factor Xa. As a result, only a slight increase in clotting time [(i.e. activated partial thomboplastin time (APTT)] is observed relative to UH. For this same reason, APTT is not used to monitor the effects of dalteparin except as an indicator for overdosage.
TargetKindPharmacological actionActionsOrganismUniProt ID
Antithrombin-IIIProteinyes
potentiator
HumanP01008 details
Vascular endothelial growth factor AProteinyes
inhibitor
HumanP15692 details
Tissue factor pathway inhibitorProteinyes
inhibitor
HumanP10646 details
P-selectinProteinunknown
inhibitor
HumanP16109 details
Related Articles
AbsorptionAlmost completely absorbed after subcutaneous (sc) doses, with a bioavialability of about 87%.
Volume of distribution

3 litres

Protein bindingLess than unfractionated heparin, which is more than 90%.
Metabolism

Liver and the reticulo-endothelial system are the sites of biotransformation. They are partially metabolized by desulphatation and depolymerization.

Route of eliminationAfter 4 hours, about 20% is seen in urine. Most of the remainder is found in the liver, gastrointestinal tract and kidney. The kidneys are the major site of dalteparin excretion (approximately 70% based on animal studies).
Half lifeTerminal Half life: Intravenous - 2 hours. Subcutaneous - 3-5hours
Clearance

Excreted via kidneys. The plasma clearance rate is 33 mL/min.

ToxicityOverdosage: hemorrhagic complications. Adverse Drug Reaction: (common) osteopenia with extended use; mild, reversible non-immunological thrombocytopenia; transient elevation of liver transaminases; alopecia. (uncommon): severe immunologically-mediated heparin-induced thrombocytopenia; anaphylactic reactions; skin rash, skin necrosis; retroperitoneal hemorrhage; angioedema
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbciximabAbciximab may increase the anticoagulant activities of Dalteparin.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Dalteparin.Approved
AcenocoumarolAcenocoumarol may increase the anticoagulant activities of Dalteparin.Approved
AcetovanilloneAcetovanillone may increase the anticoagulant activities of Dalteparin.Investigational
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Dalteparin.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Dalteparin.Approved
AliskirenDalteparin may increase the hyperkalemic activities of Aliskiren.Approved, Investigational
AllylestrenolThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Allylestrenol.Approved
AlprostadilAlprostadil may increase the anticoagulant activities of Dalteparin.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Dalteparin.Approved
AltrenogestThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Altrenogest.Vet Approved
ALX-0081ALX-0081 may increase the anticoagulant activities of Dalteparin.Investigational
AmilorideDalteparin may increase the hyperkalemic activities of Amiloride.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Dalteparin.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Dalteparin.Approved
AncrodAncrod may increase the anticoagulant activities of Dalteparin.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Dalteparin.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Dalteparin.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Dalteparin.Approved
Antithrombin III humanDalteparin may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Dalteparin.Approved
ApremilastApremilast may increase the anticoagulant activities of Dalteparin.Approved, Investigational
AprotininThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinArdeparin may increase the anticoagulant activities of Dalteparin.Approved, Withdrawn
ArgatrobanArgatroban may increase the anticoagulant activities of Dalteparin.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Dalteparin.Investigational
AzapropazoneAzapropazone may increase the anticoagulant activities of Dalteparin.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Dalteparin.Approved
Azilsartan medoxomilDalteparin may increase the hyperkalemic activities of Azilsartan medoxomil.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Dalteparin.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Dalteparin.Experimental
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Dalteparin.Approved, Investigational
BecaplerminBecaplermin may increase the anticoagulant activities of Dalteparin.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Dalteparin.Approved
BenazeprilDalteparin may increase the hyperkalemic activities of Benazepril.Approved, Investigational
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Dalteparin.Withdrawn
BeraprostBeraprost may increase the anticoagulant activities of Dalteparin.Investigational
Betulinic AcidBetulinic Acid may increase the anticoagulant activities of Dalteparin.Investigational
BivalirudinBivalirudin may increase the anticoagulant activities of Dalteparin.Approved, Investigational
BromfenacBromfenac may increase the anticoagulant activities of Dalteparin.Approved
BucillamineBucillamine may increase the anticoagulant activities of Dalteparin.Investigational
ButylphthalideButylphthalide may increase the anticoagulant activities of Dalteparin.Investigational
CanagliflozinDalteparin may increase the hyperkalemic activities of Canagliflozin.Approved
CandesartanDalteparin may increase the hyperkalemic activities of Candesartan.Approved
CandoxatrilDalteparin may increase the hyperkalemic activities of Candoxatril.Experimental
CangrelorCangrelor may increase the anticoagulant activities of Dalteparin.Approved
CaptoprilDalteparin may increase the hyperkalemic activities of Captopril.Approved
CarprofenCarprofen may increase the anticoagulant activities of Dalteparin.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Dalteparin.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Dalteparin.Approved, Investigational
CertoparinDalteparin may increase the anticoagulant activities of Certoparin.Approved
ChloroquineChloroquine may increase the anticoagulant activities of Dalteparin.Approved, Vet Approved
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Dalteparin.Withdrawn
CilazaprilDalteparin may increase the hyperkalemic activities of Cilazapril.Approved
CilostazolCilostazol may increase the anticoagulant activities of Dalteparin.Approved
Citric AcidCitric Acid may increase the anticoagulant activities of Dalteparin.Nutraceutical, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Dalteparin.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Dalteparin.Approved, Nutraceutical
CollagenaseThe risk or severity of adverse effects can be increased when Dalteparin is combined with Collagenase.Approved
Conjugated Equine EstrogensConjugated Equine Estrogens may decrease the anticoagulant activities of Dalteparin.Approved
CurcuminCurcumin may increase the anticoagulant activities of Dalteparin.Investigational
D-LimoneneD-Limonene may increase the anticoagulant activities of Dalteparin.Investigational
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidDanaparoid may increase the anticoagulant activities of Dalteparin.Approved, Withdrawn
DasatinibDasatinib may increase the anticoagulant activities of Dalteparin.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Dalteparin is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Dalteparin.Approved, Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Dalteparin is combined with Deoxycholic Acid.Approved
dersalazinedersalazine may increase the anticoagulant activities of Dalteparin.Investigational
DesirudinDalteparin may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Dalteparin.Investigational
DesogestrelThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Desogestrel.Approved
DextranDalteparin may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Dalteparin may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Dalteparin may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Dalteparin may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacDiclofenac may increase the anticoagulant activities of Dalteparin.Approved, Vet Approved
DicoumarolDicoumarol may increase the anticoagulant activities of Dalteparin.Approved
DienestrolDienestrol may decrease the anticoagulant activities of Dalteparin.Approved
DienogestThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Dalteparin.Approved
DiflunisalDiflunisal may increase the anticoagulant activities of Dalteparin.Approved
DipyridamoleDipyridamole may increase the anticoagulant activities of Dalteparin.Approved
DitazoleDitazole may increase the anticoagulant activities of Dalteparin.Approved, Withdrawn
DrospirenoneThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Drospirenone.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Dalteparin.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Dalteparin.Approved
DuvelisibDuvelisib may increase the anticoagulant activities of Dalteparin.Investigational
DydrogesteroneThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Dydrogesterone.Approved, Withdrawn
E6201E6201 may increase the anticoagulant activities of Dalteparin.Investigational
EbselenEbselen may increase the anticoagulant activities of Dalteparin.Investigational
Edetic AcidEdetic Acid may increase the anticoagulant activities of Dalteparin.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Dalteparin.Approved
EnalaprilDalteparin may increase the hyperkalemic activities of Enalapril.Approved, Vet Approved
EnalaprilatDalteparin may increase the hyperkalemic activities of Enalaprilat.Approved
EnoxaparinEnoxaparin may increase the anticoagulant activities of Dalteparin.Approved
EpinastineEpinastine may increase the anticoagulant activities of Dalteparin.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Dalteparin.Approved
EplerenoneDalteparin may increase the hyperkalemic activities of Eplerenone.Approved
eplivanserineeplivanserine may increase the anticoagulant activities of Dalteparin.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Dalteparin.Approved
EprosartanDalteparin may increase the hyperkalemic activities of Eprosartan.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Dalteparin.Approved, Investigational
EstradiolEstradiol may decrease the anticoagulant activities of Dalteparin.Approved, Investigational, Vet Approved
EstriolEstriol may decrease the anticoagulant activities of Dalteparin.Approved, Vet Approved
EstroneEstrone may decrease the anticoagulant activities of Dalteparin.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Dalteparin.Approved, Investigational
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Dalteparin.Approved
Ethyl biscoumacetateDalteparin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Ethynodiol diacetate.Approved
EtodolacEtodolac may increase the anticoagulant activities of Dalteparin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Dalteparin.Approved
EtonogestrelThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibEtoricoxib may increase the anticoagulant activities of Dalteparin.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Dalteparin.Approved
exisulindexisulind may increase the anticoagulant activities of Dalteparin.Investigational
FenbufenFenbufen may increase the anticoagulant activities of Dalteparin.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Dalteparin.Approved
FibrinolysinFibrinolysin may increase the anticoagulant activities of Dalteparin.Approved
FloctafenineFloctafenine may increase the anticoagulant activities of Dalteparin.Approved, Withdrawn
FluindioneDalteparin may increase the anticoagulant activities of Fluindione.Investigational
FlunixinFlunixin may increase the anticoagulant activities of Dalteparin.Vet Approved
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Dalteparin.Approved, Investigational
FondaparinuxDalteparin may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumFondaparinux sodium may increase the anticoagulant activities of Dalteparin.Approved, Investigational
ForasartanDalteparin may increase the hyperkalemic activities of Forasartan.Experimental
FosinoprilDalteparin may increase the hyperkalemic activities of Fosinopril.Approved
GabexateDalteparin may increase the anticoagulant activities of Gabexate.Investigational
GenisteinGenistein may decrease the anticoagulant activities of Dalteparin.Investigational
GestodeneThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Gestodene.Approved
GestrinoneThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Gestrinone.Approved
HeminHemin may increase the anticoagulant activities of Dalteparin.Approved
HeparinHeparin may increase the anticoagulant activities of Dalteparin.Approved, Investigational
HexestrolHexestrol may decrease the anticoagulant activities of Dalteparin.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Dalteparin.Investigational
HirulogHirulog may increase the anticoagulant activities of Dalteparin.Experimental
HMPL-004HMPL-004 may increase the anticoagulant activities of Dalteparin.Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Dalteparin is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Dalteparin.Approved
IbudilastIbudilast may increase the anticoagulant activities of Dalteparin.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Dalteparin.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Dalteparin.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Dalteparin.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Dalteparin.Approved, Nutraceutical
idraparinuxDalteparin may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Dalteparin.Approved, Withdrawn
IloprostIloprost may increase the anticoagulant activities of Dalteparin.Approved, Investigational
ImidaprilDalteparin may increase the hyperkalemic activities of Imidapril.Investigational
IndobufenIndobufen may increase the anticoagulant activities of Dalteparin.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Dalteparin.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Dalteparin.Withdrawn
IrbesartanDalteparin may increase the hyperkalemic activities of Irbesartan.Approved, Investigational
IsoxicamIsoxicam may increase the anticoagulant activities of Dalteparin.Withdrawn
Kct 0809Kct 0809 may increase the anticoagulant activities of Dalteparin.Investigational
KebuzoneKebuzone may increase the anticoagulant activities of Dalteparin.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Dalteparin.Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Dalteparin.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Dalteparin.Approved
LeflunomideLeflunomide may increase the anticoagulant activities of Dalteparin.Approved, Investigational
LepirudinLepirudin may increase the anticoagulant activities of Dalteparin.Approved
LevonorgestrelThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Dalteparin.Approved
LisinoprilDalteparin may increase the hyperkalemic activities of Lisinopril.Approved, Investigational
LisofyllineLisofylline may increase the anticoagulant activities of Dalteparin.Investigational
LornoxicamLornoxicam may increase the anticoagulant activities of Dalteparin.Approved
LosartanDalteparin may increase the hyperkalemic activities of Losartan.Approved
LoxoprofenLoxoprofen may increase the anticoagulant activities of Dalteparin.Approved
LumiracoxibLumiracoxib may increase the anticoagulant activities of Dalteparin.Approved, Investigational
LynestrenolThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Lynestrenol.Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Dalteparin.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Dalteparin.Approved
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Dalteparin.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Dalteparin.Approved
Megestrol acetateThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MeloxicamMeloxicam may increase the anticoagulant activities of Dalteparin.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Dalteparin.Approved
MestranolMestranol may decrease the anticoagulant activities of Dalteparin.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Dalteparin.Withdrawn
MethallenestrilMethallenestril may decrease the anticoagulant activities of Dalteparin.Experimental
MilrinoneMilrinone may increase the anticoagulant activities of Dalteparin.Approved
MizoribineMizoribine may increase the anticoagulant activities of Dalteparin.Investigational
MoexiprilDalteparin may increase the hyperkalemic activities of Moexipril.Approved
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Dalteparin.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Dalteparin.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Dalteparin.Approved
NadroparinDalteparin may increase the anticoagulant activities of Nadroparin.Approved
NafamostatNafamostat may increase the anticoagulant activities of Dalteparin.Investigational
NaftifineNaftifine may increase the anticoagulant activities of Dalteparin.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Dalteparin.Investigational
NaproxenNaproxen may increase the anticoagulant activities of Dalteparin.Approved, Vet Approved
NCX 4016NCX 4016 may increase the anticoagulant activities of Dalteparin.Investigational
NepafenacNepafenac may increase the anticoagulant activities of Dalteparin.Approved
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Dalteparin.Approved
NimesulideNimesulide may increase the anticoagulant activities of Dalteparin.Approved, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Dalteparin is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Dalteparin.Investigational
NomegestrolThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Norethisterone.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Dalteparin is combined with Obinutuzumab.Approved
OlmesartanDalteparin may increase the hyperkalemic activities of Olmesartan.Approved, Investigational
OlopatadineOlopatadine may increase the anticoagulant activities of Dalteparin.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Dalteparin.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Dalteparin is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatDalteparin may increase the hyperkalemic activities of Omapatrilat.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Dalteparin.Approved
OrgoteinOrgotein may increase the anticoagulant activities of Dalteparin.Vet Approved
OtamixabanOtamixaban may increase the anticoagulant activities of Dalteparin.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Dalteparin.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Dalteparin.Withdrawn
PaliferminThe serum concentration of Palifermin can be increased when it is combined with Dalteparin.Approved
ParecoxibParecoxib may increase the anticoagulant activities of Dalteparin.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Dalteparin.Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Dalteparin.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Dalteparin.Approved, Investigational
PerindoprilDalteparin may increase the hyperkalemic activities of Perindopril.Approved
PhenindionePhenindione may increase the anticoagulant activities of Dalteparin.Approved
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Dalteparin.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Dalteparin.Approved, Vet Approved
PimecrolimusPimecrolimus may increase the anticoagulant activities of Dalteparin.Approved, Investigational
PirfenidonePirfenidone may increase the anticoagulant activities of Dalteparin.Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Dalteparin.Approved, Investigational
PlasminPlasmin may increase the anticoagulant activities of Dalteparin.Investigational
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Dalteparin.Approved
PrasugrelPrasugrel may increase the anticoagulant activities of Dalteparin.Approved
ProgesteroneThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Progesterone.Approved, Vet Approved
PromestrienePromestriene may decrease the anticoagulant activities of Dalteparin.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Dalteparin.Approved
Protein CDalteparin may increase the anticoagulant activities of Protein C.Approved
Protein S humanDalteparin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeDalteparin may increase the anticoagulant activities of Protocatechualdehyde.Approved
PTC299PTC299 may increase the anticoagulant activities of Dalteparin.Investigational
QuinaprilDalteparin may increase the hyperkalemic activities of Quinapril.Approved, Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Dalteparin.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Dalteparin.Investigational
RamiprilDalteparin may increase the hyperkalemic activities of Ramipril.Approved
RescinnamineDalteparin may increase the hyperkalemic activities of Rescinnamine.Approved
ResveratrolResveratrol may increase the anticoagulant activities of Dalteparin.Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Dalteparin.Approved
ReviparinDalteparin may increase the anticoagulant activities of Reviparin.Approved
RidogrelRidogrel may increase the anticoagulant activities of Dalteparin.Approved
RivaroxabanDalteparin may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Dalteparin.Investigational, Withdrawn
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Dalteparin.Approved, Investigational
S EquolS Equol may decrease the anticoagulant activities of Dalteparin.Investigational
SacubitrilDalteparin may increase the hyperkalemic activities of Sacubitril.Approved
SalicylamideSalicylamide may increase the anticoagulant activities of Dalteparin.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Dalteparin.Approved, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Dalteparin.Approved
SaprisartanDalteparin may increase the hyperkalemic activities of Saprisartan.Experimental
SaralasinDalteparin may increase the hyperkalemic activities of Saralasin.Investigational
SCH-530348SCH-530348 may increase the anticoagulant activities of Dalteparin.Investigational
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Dalteparin.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Dalteparin.Approved
SeratrodastSeratrodast may increase the anticoagulant activities of Dalteparin.Approved, Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Dalteparin.Approved, Vet Approved
SpiraprilDalteparin may increase the hyperkalemic activities of Spirapril.Approved
SpironolactoneDalteparin may increase the hyperkalemic activities of Spironolactone.Approved
SRT501SRT501 may increase the anticoagulant activities of Dalteparin.Investigational
StreptokinaseStreptokinase may increase the anticoagulant activities of Dalteparin.Approved
SugammadexSugammadex may increase the anticoagulant activities of Dalteparin.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Dalteparin.Approved
SulindacSulindac may increase the anticoagulant activities of Dalteparin.Approved
SulodexideSulodexide may increase the anticoagulant activities of Dalteparin.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Dalteparin.Approved, Withdrawn
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Dalteparin.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Dalteparin.Approved
TasosartanDalteparin may increase the hyperkalemic activities of Tasosartan.Approved
TelmisartanDalteparin may increase the hyperkalemic activities of Telmisartan.Approved, Investigational
TemocaprilDalteparin may increase the hyperkalemic activities of Temocapril.Experimental, Investigational
TenecteplaseTenecteplase may increase the anticoagulant activities of Dalteparin.Approved
TenoxicamTenoxicam may increase the anticoagulant activities of Dalteparin.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Dalteparin.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Dalteparin.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Dalteparin.Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Dalteparin.Approved
TiboloneTibolone may increase the anticoagulant activities of Dalteparin.Approved
TicagrelorTicagrelor may increase the anticoagulant activities of Dalteparin.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Dalteparin.Approved
TinoridineTinoridine may increase the anticoagulant activities of Dalteparin.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Dalteparin.Approved
TipranavirTipranavir may increase the anticoagulant activities of Dalteparin.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Dalteparin.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Dalteparin.Approved
TolmetinTolmetin may increase the anticoagulant activities of Dalteparin.Approved
TositumomabThe risk or severity of adverse effects can be increased when Dalteparin is combined with Tositumomab.Approved
TrandolaprilDalteparin may increase the hyperkalemic activities of Trandolapril.Approved
TranilastTranilast may increase the anticoagulant activities of Dalteparin.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Dalteparin.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Dalteparin.Approved, Investigational
TriamtereneDalteparin may increase the hyperkalemic activities of Triamterene.Approved
TriflusalTriflusal may increase the anticoagulant activities of Dalteparin.Approved
Trisalicylate-cholineTrisalicylate-choline may increase the anticoagulant activities of Dalteparin.Approved
UrokinaseUrokinase may increase the anticoagulant activities of Dalteparin.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Dalteparin.Investigational, Withdrawn
ValsartanDalteparin may increase the hyperkalemic activities of Valsartan.Approved, Investigational
Vitamin EVitamin E may increase the anticoagulant activities of Dalteparin.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Dalteparin.Approved
WarfarinWarfarin may increase the anticoagulant activities of Dalteparin.Approved
XimelagatranXimelagatran may increase the anticoagulant activities of Dalteparin.Approved, Investigational, Withdrawn
Ym150Dalteparin may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Dalteparin.Approved
ZeranolZeranol may decrease the anticoagulant activities of Dalteparin.Vet Approved
ZileutonZileuton may increase the anticoagulant activities of Dalteparin.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the anticoagulant activities of Dalteparin.Withdrawn
Food Interactions
  • Herbs (anticoagulant/antiplatelet properties such as ginseng, ginkgo, ginger, garlic)
References
Synthesis ReferenceNot Available
General References
  1. King DJ, Kelton JG: Heparin-associated thrombocytopenia. Ann Intern Med. 1984 Apr;100(4):535-40. [PubMed:6367579 ]
  2. Bell WR, Royall RM: Heparin-associated thrombocytopenia: a comparison of three heparin preparations. N Engl J Med. 1980 Oct 16;303(16):902-7. [PubMed:6997743 ]
  3. Ockelford PA, Patterson J, Johns AS: A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin). Thromb Haemost. 1989 Dec 29;62(4):1046-9. [PubMed:2559484 ]
  4. Hartl P, Brucke P, Dienstl E, Vinazzer H: Prophylaxis of thromboembolism in general surgery: comparison between standard heparin and Fragmin. Thromb Res. 1990 Feb 15;57(4):577-84. [PubMed:2158151 ]
  5. Monreal M, Lafoz E, Salvador R, Roncales J, Navarro A: Adverse effects of three different forms of heparin therapy: thrombocytopenia, increased transaminases, and hyperkalaemia. Eur J Clin Pharmacol. 1989;37(4):415-8. [PubMed:2557219 ]
  6. Holmer E, Soderberg K, Bergqvist D, Lindahl U: Heparin and its low molecular weight derivatives: anticoagulant and antithrombotic properties. Haemostasis. 1986;16 Suppl 2:1-7. [PubMed:3744129 ]
  7. Malm K, Dahlback B, Arnljots B: Low-molecular-weight heparin (dalteparin) effectively prevents thrombosis in a rat model of deep arterial injury. Plast Reconstr Surg. 2003 Apr 15;111(5):1659-66. [PubMed:12655212 ]
  8. Tincani E, Mannucci C, Casolari B, Turrini F, Crowther MA, Prisco D, Cenci AM, Bondi M: Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. Haematologica. 2006 Jul;91(7):976-9. Epub 2006 Jun 1. [PubMed:16757417 ]
  9. Schmid P, Brodmann D, Fischer AG, Wuillemin WA: Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function. J Thromb Haemost. 2009 Apr;7(4):552-8. doi: 10.1111/j.1538-7836.2009.03292.x. Epub 2009 Jan 19. [PubMed:19175499 ]
  10. Abe W, Ikejima K, Lang T, Okumura K, Enomoto N, Kitamura T, Takei Y, Sato N: Low molecular weight heparin prevents hepatic fibrogenesis caused by carbon tetrachloride in the rat. J Hepatol. 2007 Feb;46(2):286-94. Epub 2006 Oct 25. [PubMed:17166617 ]
  11. Frydman A: Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26 Suppl 2:24-38. [PubMed:8707165 ]
  12. Samama MM, Gerotziafas GT: Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost. 2000;26 Suppl 1:31-8. [PubMed:11011804 ]
  13. Rey E, Rivard GE: Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. Int J Gynaecol Obstet. 2000 Oct;71(1):19-24. [PubMed:11044537 ]
External Links
ATC CodesB01AB04
AHFS Codes
  • 20:12.04.16
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET featuresNot Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
InjectionSubcutaneous10000 [iU]/.4mL
InjectionSubcutaneous10000 [iU]/mL
InjectionSubcutaneous12500 [iU]/.5mL
InjectionSubcutaneous15000 [iU]/.6mL
InjectionSubcutaneous18000 [iU]/.72mL
InjectionSubcutaneous2500 [iU]/.2mL
InjectionSubcutaneous25000 [iU]/mL
InjectionSubcutaneous5000 [iU]/.2mL
InjectionSubcutaneous7500 [iU]/.3mL
SolutionIntravenous; Subcutaneous10000 unit
SolutionIntravenous; Subcutaneous12500 unit
SolutionIntravenous; Subcutaneous15000 unit
SolutionIntravenous; Subcutaneous18000 unit
SolutionIntravenous; Subcutaneous2500 unit
SolutionIntravenous; Subcutaneous25000 unit
SolutionIntravenous; Subcutaneous3500 unit
SolutionIntravenous; Subcutaneous5000 unit
SolutionIntravenous; Subcutaneous7500 unit
LiquidIntravenous; Subcutaneous2500 unit
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted PropertiesNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Taxonomy
ClassificationNot classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Serine-type endopeptidase inhibitor activity
Specific Function:
Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. Its inhibitory activity is greatly enhanced in the presence of heparin.
Gene Name:
SERPINC1
Uniprot ID:
P01008
Molecular Weight:
52601.935 Da
References
  1. Frydman A: Low-molecular-weight heparins: an overview of their pharmacodynamics, pharmacokinetics and metabolism in humans. Haemostasis. 1996;26 Suppl 2:24-38. [PubMed:8707165 ]
  2. Rey E, Rivard GE: Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. Int J Gynaecol Obstet. 2000 Oct;71(1):19-24. [PubMed:11044537 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Vascular endothelial growth factor receptor binding
Specific Function:
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activ...
Gene Name:
VEGFA
Uniprot ID:
P15692
Molecular Weight:
27042.205 Da
References
  1. Norrby K, Nordenhem A: Dalteparin, a low-molecular-weight heparin, promotes angiogenesis mediated by heparin-binding VEGF-A in vivo. APMIS. 2010 Dec;118(12):949-57. doi: 10.1111/j.1600-0463.2010.02635.x. Epub 2010 Oct 12. [PubMed:21091776 ]
  2. Marchetti M, Vignoli A, Russo L, Balducci D, Pagnoncelli M, Barbui T, Falanga A: Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thromb Res. 2008;121(5):637-45. Epub 2007 Aug 10. [PubMed:17692905 ]
  3. Takahashi H, Ebihara S, Okazaki T, Asada M, Sasaki H, Yamaya M: A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity. Br J Pharmacol. 2005 Oct;146(3):333-43. [PubMed:16041398 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serine-type endopeptidase inhibitor activity
Specific Function:
Inhibits factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex. It possesses an antithrombotic action and also the ability to associate with lipoproteins in plasma.
Gene Name:
TFPI
Uniprot ID:
P10646
Molecular Weight:
35014.835 Da
References
  1. Mousa SA: Low-molecular-weight heparins in thrombosis and cancer: emerging links. Cardiovasc Drug Rev. 2004 Summer;22(2):121-34. [PubMed:15179449 ]
  2. Naumnik B, Rydzewska-Rosolowska A, Mysliwiec M: Different effects of enoxaparin, nadroparin, and dalteparin on plasma TFPI during hemodialysis: a prospective crossover randomized study. Clin Appl Thromb Hemost. 2011 Oct;17(5):480-6. doi: 10.1177/1076029610376936. Epub 2010 Aug 3. [PubMed:20682597 ]
  3. Bendz B, Andersen TO, Sandset PM: Dose-dependent release of endogenous tissue factor pathway inhibitor by different low molecular weight heparins. Blood Coagul Fibrinolysis. 2000 Jun;11(4):343-8. [PubMed:10847421 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sialic acid binding
Specific Function:
Ca(2+)-dependent receptor for myeloid cells that binds to carbohydrates on neutrophils and monocytes. Mediates the interaction of activated endothelial cells or platelets with leukocytes. The ligand recognized is sialyl-Lewis X. Mediates rapid rolling of leukocyte rolling over vascular surfaces during the initial steps in inflammation through interaction with PSGL1.
Gene Name:
SELP
Uniprot ID:
P16109
Molecular Weight:
90833.105 Da
References
  1. Rey E, Rivard GE: Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. Int J Gynaecol Obstet. 2000 Oct;71(1):19-24. [PubMed:11044537 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Syndecan binding
Specific Function:
Endoglycosidase that cleaves heparan sulfate proteoglycans (HSPGs) into heparan sulfate side chains and core proteoglycans. Participates in extracellular matrix (ECM) degradation and remodeling. Selectively cleaves the linkage between a glucuronic acid unit and an N-sulfo glucosamine unit carrying either a 3-O-sulfo or a 6-O-sulfo group. Can also cleave the linkage between a glucuronic acid uni...
Gene Name:
HPSE
Uniprot ID:
Q9Y251
Molecular Weight:
61148.17 Da
References
  1. Takahashi H, Ebihara S, Okazaki T, Asada M, Sasaki H, Yamaya M: A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity. Br J Pharmacol. 2005 Oct;146(3):333-43. [PubMed:16041398 ]
Comments
comments powered by Disqus
Drug created on September 14, 2010 10:21 / Updated on August 17, 2016 12:24